enicepatide vs olatorepatide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline

enicepatide

Developed by Roche and partners

Phase 3 in Obesitypeptide
Reliable signal

NCT06525935 · Phase 2 · completed

This was a randomized, double-blind, placebo-controlled Phase 2 trial in 469 adults with obesity and at least one weight-related condition. Enicepatide 24 mg produced significantly greater weight loss than placebo at week 48, 22.5% placebo-adjusted by one analysis method and 18.3% by another, both p<0.001, meeting the trial primary comparison.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: November 2027 · NCT07589686 (registry estimate)

Reported efficacy

Percent Change in Body Weight from Baseline to Week 48: Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001) (met)

Result source: NCT06525935

olatorepatide

Developed by Regeneron Pharmaceuticals under a licence from Hansoh Pharmaceutical Group

Phase 3 in Obesitypeptide
Reliable signal

NCT06839664 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial (n=604). The co-primary endpoints, percent weight change and the proportion achieving at least 5% weight loss at week 48, were both met: participants lost up to 19.3% of body weight and up to 97.2% achieved at least 5% weight loss, both significantly better than placebo.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: January 2028 · NCT07685808 (registry estimate)

Reported efficacy

Percent Change from Baseline in Body Weight (Baseline, week 48); Percentage of Participants Who Achieve weight loss≥ 5% from Baseline (Baseline, week 48): Co-primary endpoints met at Week 48: up to 19.3% mean weight loss with olatorepatide from baseline (dose range 5/10/15mg); up to 97.2% of participants achieved ≥5% weight loss, statistically significant vs placebo. (met)

Result source: NCT06839664

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointenicepatideolatorepatide
Body weight, % change—Trial running · NCT07670416—Not posted · NCT06839664
Weight loss of 5% or more—Trial running · NCT07670416—Not posted · NCT06839664
Weight loss of 10% or more—Trial running · NCT07670416—Not posted · NCT06839664
Waist circumference, change (cm)—Trial running · NCT07670416—Not posted · NCT06839664

Body weight, % change

enicepatide
—Trial running · NCT07670416
olatorepatide
—Not posted · NCT06839664

Weight loss of 5% or more

enicepatide
—Trial running · NCT07670416
olatorepatide
—Not posted · NCT06839664

Weight loss of 10% or more

enicepatide
—Trial running · NCT07670416
olatorepatide
—Not posted · NCT06839664

Waist circumference, change (cm)

enicepatide
—Trial running · NCT07670416
olatorepatide
—Not posted · NCT06839664
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

enicepatide
Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001) NCT06525935 · Phase 2 · design grade: strong · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

olatorepatide

Weight 19.3% @ 48wk
percent change · % of baseline
No placebo or comparator arm
NCT06839664 · Phase 3 · sponsor-reported, not registry data
Weight Loss 5% 97.2% @ 48wk
responder rate · % of participants
No placebo or comparator arm
NCT06839664 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: enicepatide's landscape · olatorepatide's landscape